Clinical and economic comparison of epoetin alfa and darbepoetin alfa

References

• Epoetin alfa [package insert]. Bridgewater, NJ: Ortho Biotech Products, L.P.; 2002
   Google Scholar
• Darbepoetin alfa [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2002
   Google Scholar
• Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53–61
   PubMed Web of Science ®Google Scholar
• Sunder-Plassmann G, Horl WH. Effect of erythropoietin on cardiovascular diseases. Am J Kidney Dis 2001;38(Suppl 1):S20–5
   PubMedGoogle Scholar
• Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35:250–6
   PubMed Web of Science ®Google Scholar
• Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002;95:155–63
   PubMed Web of Science ®Google Scholar
• Denton TA, Diamond GA, Matloff JM, Gray RJ. Anemia therapy: individual benefit and societal cost. Semin Oncol 1994;21:29–35
   PubMed Web of Science ®Google Scholar
• Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994;73:2535–42
   PubMed Web of Science ®Google Scholar
• Marsh JT, Brown WS, Wolcott D, Carr CR, Harper R, Schweitzer SV, et al. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 1991;39:155–63
   PubMed Web of Science ®Google Scholar
• Barnett A, Birnbaum H, Cremieux P-Y, Fendrick AM, Slavin M. The costs of cancer to a major employer in the United States: a case-control analysis. Am J Manag Care 2000;6:1243–51
   PubMed Web of Science ®Google Scholar
• Barnett A, Cremieux P-Y, Fendrick AM, George M, Slavin MB. Anemia-related costs for cancer patients. J Manag Care Med 2002;6:20–8
   Google Scholar
• Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 2000;11:335–42
   PubMed Web of Science ®Google Scholar
• US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991;18:50–9
   PubMed Web of Science ®Google Scholar
• Wolcott DL, Marsh JT, La Rue A, Carr C, Nissenson AR. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989;14:478–85
   PubMed Web of Science ®Google Scholar
• Crawford J, Cella D, Cleeland CS, Cremieux P-Y, Demetri GD, Sarokhan BJ, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888–95
   PubMed Web of Science ®Google Scholar
• Gillespie TW. Effects of cancer-related anemia on clinical and quality-of-life outcomes. Clin J Oncol Nurs 2002;6:206–11
   PubMedGoogle Scholar
• Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993;29A(Suppl 2):S2–8
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–74
   PubMed Web of Science ®Google Scholar
• Basskins L. Pharmacoeconomics and the formulary decision-making process. Formulary 1998;33:459–66
   Web of Science ®Google Scholar
• Garrelts JC. Pharmacoeconomics: disease-based management applications. Pharm Pract Manag Q 1996;16:36–40
   PubMedGoogle Scholar
• Schulman KA, Linas BP. Pharmacoeconomics: state of the art in 1997. Annu Rev Pub Health 1997;18:529–48
   PubMed Web of Science ®Google Scholar
• Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. Br J Clin Pharmacol 1997;43:343–8
   PubMed Web of Science ®Google Scholar
• Lafata JE, Koch GG, Ward RE. Synthesizing evidence from multiple studies: the role of meta-analysis in pharmacoeconomics. Med Care 1996;34:DS136-DS145
   PubMed Web of Science ®Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84:3–10
   PubMed Web of Science ®Google Scholar
• Ibbotson T, Goa KL. Darbepoetin alfa. Drugs 2001;61:2097–104
   PubMed Web of Science ®Google Scholar
• Macdougall IC. Optimizing the use of erythropoietic agents – pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002;17:66–70
   PubMed Web of Science ®Google Scholar
• Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 2001;84(Suppl 1):11–6
   PubMed Web of Science ®Google Scholar
• Elliott SG, Lorenzini T, Strickland T, Delorme E, Egrie JC. Rational design of novel erythropoiesis stimulating protein (AranespTM): a super-sialated molecule with increased biological activity. Blood 2000;96(Suppl):82a-3a[Abstr 352]
   Web of Science ®Google Scholar
• Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001;57:411–8
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392–5
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989;1:425–7
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875–82
   PubMed Web of Science ®Google Scholar
• Petroff S, Germain M, O’Shea M, Braden G, Sweet S, Mulhern J. Prolonged erythropoietin (EPO) dosing intervals in pre-ESRD patients [Abstr A2098], ASN/ISN World Congress of Nephrology, October 13–17, 2001, San Francisco, California
   Google Scholar
• Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Blood 2000;96(Pt 1):434a[Abstr 1866]
   Google Scholar
• National Kidney Foundation. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37:S182–238
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268–76
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 2003;97:1312–20
   PubMed Web of Science ®Google Scholar
• Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741–7
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002;62:2167–75
   PubMed Web of Science ®Google Scholar
• Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:110–8
   PubMed Web of Science ®Google Scholar
• Coyne D, Ling BN, Toto R, McDermott-Vitak AD, Trotman ML, Jackson L. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO) [Abstr SU624], 33rd Annual Meeting of the American Society of Nephrology, October 13–16, 2000, Toronto, Canada
   Google Scholar
• Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211–20
   PubMed Web of Science ®Google Scholar
• Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 2001;84(Suppl 1):17–23
   PubMed Web of Science ®Google Scholar
• Kotasek D, Albertsson M, Mackey J. Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3W) of 4 (Q4W) weeks in patients with solid tumors [Abstr 1268], 42nd Annual Meeting of the American Society of Hematology, December 1–5, 2000, San Francisco, California
   Google Scholar
• Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich B, Dewey C, et al. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79–86
   PubMed Web of Science ®Google Scholar
• Smith RE Jr, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 2001;84(Suppl 1):24–30
   Google Scholar
• Smith R, Tchekmedyian S, Chan D, Meza L, Jaiyesimi I, Fleishman A, et al. Open-label, phase I/II dose escalation study of NESP in patients with chronic anemia of cancer. Eur J Cancer 2001;37(Suppl 6):S355[Abstr 132]
   Google Scholar
• Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, et al. Epoetin alfa in patients not on chemotherapy – Canadian data. Semin Oncol 2002;29:75–80
   PubMed Web of Science ®Google Scholar
• Thomson PDR. 2003 Drug Topics^® Red Book. Montvale(NJ): Thomson PDR, 2003
   Google Scholar
• Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73–8
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992–1000
   PubMed Web of Science ®Google Scholar
• Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003;18:362–9
   PubMed Web of Science ®Google Scholar
• Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218–34
   PubMed Web of Science ®Google Scholar
• Demetri GD, Glaspy J, Gabrilove J. Hematologic and quality of life benefits of epoetin alfa once weekly vs 3 times weekly in patients with hematologic malignancies. Hematol J 2001;1:59 [Abstr 193]
   Google Scholar
• Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003;14:511–9
   PubMed Web of Science ®Google Scholar
• Rosberg J, McKenzie RS, Myers T, Lefebvre P, Koch R. Clinical significance of early response to epoetin alfa (EPO) therapy [Poster], Outcomes Management Conference, September 17, 2003, Chicago, Illinois
   Google Scholar
• Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083–107
   PubMed Web of Science ®Google Scholar
• Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;19:4126–34
   PubMed Web of Science ®Google Scholar
• Cremieux PY, Fastenau J, Fendrick AM, Kosicki G, Piech CT. Cost-effectiveness of once-weekly dosing of epoetin alfa (Procrit®) for chemotherapy-related anemia [Poster], American Society of Health-System Pharmacists, June 3, 2003
   Google Scholar
• Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412–25
   PubMed Web of Science ®Google Scholar